Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.

Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical outcomes in patients with favorable-risk disease. It is unclear whether the addition of GO to cytarabine and anthracycline chemotherapy (7+3) improves clinical outcomes compared with other conventional regimens for AML.

The Social Risk ACTIONS Framework: Characterizing Responses to Social Risks by Health Care Delivery Organizations.

Social risks refer to individuals' social and economic conditions shaped by underlying social determinants of health. Health care delivery organizations increasingly screen patients for social risks given their potential impact on health outcomes. However, it can be challenging to meaningfully address patients' needs.

Prioritizing Veteran Social Well-Being: A Call to Action.

The Department of Veteran Affairs (VA) has an increased interest in addressing the well-being and whole health of Veterans. In March of 2023, the VA convened a conference to discuss whole-person outcomes of relevance for Veterans in clinical, research, and population health areas. Based upon perceptions from conference participants who are Veteran community members, the aim of this manuscript is to offer a Veteran community perspective on the importance of prioritizing social well-being as part of VA Whole Health programming.